Active Ingredient History
Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Osteitis Deformans (approved 1998)
Adenocarcinoma (Phase 4)
Alveolar Bone Loss (Phase 4)
Anorexia Nervosa (Phase 2/Phase 3)
Back Pain (Phase 3)
Bariatric Surgery (Phase 4)
Biological Availability (Phase 1)
Bone Diseases, Metabolic (Phase 4)
Breast Neoplasms (Phase 4)
Bursitis (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Cesarean Section (Phase 4)
Colles' Fracture (Phase 4)
Crohn Disease (Phase 4)
Cystic Fibrosis (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Epilepsy (Phase 4)
Femoral Neck Fractures (Phase 4)
Fibrosis (Phase 4)
Fibrous Dysplasia of Bone (Phase 2/Phase 3)
Fractures, Bone (Phase 4)
General Surgery (Phase 1)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 3)
HIV Infections (Phase 1)
Hypertension (Phase 4)
Leukemia (Phase 3)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 3)
Menopause (Phase 3)
Muscular Dystrophies (Phase 4)
Osteitis Deformans (Phase 3)
Osteogenesis Imperfecta (Phase 4)
Osteoporosis ()
Osteoporosis, Postmenopausal (Phase 4)
Osteoporotic Fractures (Phase 4)
Periodontal Diseases (Phase 4)
Peritonitis (Phase 4)
Postmenopause (Phase 2)
Prostatic Neoplasms (Phase 4)
Prosthesis Failure (Phase 3)
Renal Insufficiency, Chronic (Phase 3)
Sexual Dysfunctions, Psychological (Phase 3)
Spinal Cord Injuries (Phase 3)
Spinal Fractures (Phase 3)
Spondylitis, Ankylosing (Phase 2)
Weight Loss (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
